Amgen Inc
NASDAQ:AMGN

  • LAST PRICE
    308.1600
  • TODAY'S CHANGE (%)
    -1.7300 (-0.5583%)
  • Bid / Lots
    308.1600/ 3
  • Ask / Lots
    310.7800/ 1
  • Open / Previous Close
    313.1300 / 309.8900
  • Day Range
    307.2900
    313.4400
  • 52 Week Range
    218.4400
    329.7200
  • Volume
    6,566,820

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Yesterday

  • Jun 19, 2024

      Show headlines and story abstract

    • 1:30AM ET on Wednesday Jun 19, 2024 by Dow Jones
      Companies Mentioned: MSFT, ADBE, AMGN, BMY, CRM

      By Jacob Sonenshine

      Mergers are back -- and that means opportunity for small-cap investors.

      Small-caps don't have a lot going for them. The Russell 2000 index has gained 0.2% this year, lagging the S&P 500's 15% return. But they do have one thing in their favor: This year, there has been $847 billion of merger and acquisition activity in the Americas, up 43% over the same period last year, according to LSEG Group. That puts activity on pace to hit just over $1.87 trillion for the entire year, only a few hundred billion dollars below the 2021 peak. And small-cap companies are usually the target.

  • Jun 14, 2024

      Show headlines and story abstract

    • 4:43PM ET on Friday Jun 14, 2024 by MT Newswires
      Companies Mentioned: AMGN
      04:43 PM EDT, 06/14/2024 (MT Newswires) -- Amgen (AMGN) said late Friday the US Food and Drug Administration has cleared Blincyto to treat adults and children one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor ac...

    • 4:43PM ET on Friday Jun 14, 2024 by Dow Jones
      Companies Mentioned: AMGN

      By Sabela Ojea

      Amgen said the Food and Drug Administration has approved Blincyto to treat an aggressive type of blood cancer.

      The biotechnology company on Friday said the approval is aimed at adult and pediatric patients one month or older with CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia.

    • 4:21PM ET on Friday Jun 14, 2024 by Dow Jones
      Companies Mentioned: AMGN

      This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa-Kirin Co., Ltd.), the performance of Otezla(R) (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), the Teneobio, Inc. acquisition, the ChemoCentryx, Inc. acquisition, or the Horizon Therapeutics plc acquisition (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition), and any projected impacts from the Horizon acquisition on our acquisition related expenses going forward, as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.

Peers Headlines